logo

FDA Calendar

Share
Company Name Amarin Corp Plc
Drug Name Vascepa (sNDA)
Event Name FDA decision on expansion of Vascepa labeling based on the REDUCE-IT cardiovascular outcomes study.
Event Date 12/28/2019
Outcome Date
Outcome
Drug Status Vascepa (icosapent ethyl) is already approved as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia.
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar

>